FASENRA is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.1
FASENRA‘s safety profile is being studied in an extensive respiratory Phase III programme5,7,9, 16-19
Safety results from pivotal clinical studies (n = 2,514) of 48 to 56 weeks duration:1
The most commonly reported adverse reactions were headache and pharyngitis.*1
The frequency of common adverse events is defined as ≥ 1/100 to <1/101
- Injection site reactions (e.g. pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo.1
- FASENRA is contraindicated in any patients with known hypersensitivity to the active substance or to any of the excipients.1
*Pharyngitis was defined by the following grouped preferred terms: ‘Pharyngitis’, ‘Pharyngitis bacterial’, ‘Viral pharyngitis’, ‘Pharyngitis streptococcal’.
†Hypersensitivity reactions were defined by the following grouped preferred terms: ‘Urticaria’, ‘Papular urticaria’, and ‘Rash’.